Emergent BioSolutions, Inc. (EBS)
6.02
+0.11
(+1.86%)
USD |
NYSE |
Aug 31, 10:41
Emergent BioSolutions Free Cash Flow : 85.90M for June 30, 2026
Free Cash Flow Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Free Cash Flow Data
| Date | Value |
|---|---|
| June 30, 2026 | 85.90M |
| March 31, 2026 | 135.40M |
| December 31, 2025 | 156.80M |
| September 30, 2025 | 1.40M |
| June 30, 2025 | 155.00M |
| March 31, 2025 | 94.40M |
| December 31, 2024 | 35.80M |
| September 30, 2024 | 138.10M |
| June 30, 2024 | 37.60M |
| March 31, 2024 | -132.20M |
| December 31, 2023 | -257.90M |
| September 30, 2023 | -209.40M |
| June 30, 2023 | -602.40M |
| March 31, 2023 | -523.20M |
| December 31, 2022 | -393.60M |
| September 30, 2022 | -180.50M |
| June 30, 2022 | 126.60M |
| March 31, 2022 | 77.60M |
| December 31, 2021 | 96.10M |
| September 30, 2021 | 22.90M |
| June 30, 2021 | 120.90M |
| March 31, 2021 | 310.40M |
| December 31, 2020 | 395.00M |
| September 30, 2020 | 271.90M |
| June 30, 2020 | 194.00M |
| Date | Value |
|---|---|
| March 31, 2020 | 51.30M |
| December 31, 2019 | 101.10M |
| September 30, 2019 | -171.49M |
| June 30, 2019 | -5.174M |
| March 31, 2019 | 65.71M |
| December 31, 2018 | -30.30M |
| September 30, 2018 | 222.79M |
| June 30, 2018 | 95.62M |
| March 31, 2018 | 119.34M |
| December 31, 2017 | 153.31M |
| September 30, 2017 | 57.62M |
| June 30, 2017 | 21.48M |
| March 31, 2017 | -25.36M |
| December 31, 2016 | -22.77M |
| September 30, 2016 | -1.693M |
| June 30, 2016 | 104.51M |
| March 31, 2016 | 98.56M |
| December 31, 2015 | -0.353M |
| September 30, 2015 | 43.53M |
| June 30, 2015 | 26.42M |
| March 31, 2015 | 40.52M |
| December 31, 2014 | 81.64M |
| September 30, 2014 | 46.92M |
| June 30, 2014 | 13.04M |
| March 31, 2014 | 33.42M |
Free Cash Flow Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Free Cash Flow Benchmarks
| Exelixis, Inc. | 1.172B |
| Capricor Therapeutics, Inc. | -129.78M |
| ADMA Biologics, Inc. | 116.22M |
| Akebia Therapeutics, Inc. | 40.26M |
| Arcutis Biotherapeutics, Inc. | 39.15M |
Free Cash Flow Related Metrics
| Cash from Operations (Quarterly) | 56.10M |
| Cash from Investing (Quarterly) | -52.30M |
| Cash from Financing (Quarterly) | -24.40M |
| Free Cash Flow Per Share (Quarterly) | 1.046 |
| Free Cash Flow to Equity (Quarterly) | 100.80M |
| Free Cash Flow to Firm (Quarterly) | 64.84M |
| Free Cash Flow Yield | 26.30% |